Comparative efficacy and safety of adalimumab biosimilar (BCD-057) and innovator in patients with psoriasis vulgaris. Results of the BCD-057-2/CALYPSO phase III international, multicenter, randomized double-blind clinical trial
The paper gives the results of the phase III clinical trial of adalimumab (ADA) biosimilar, (BCD-057) (BIOCAD, Russia), which demonstrate the clinical equivalence of the biosimilar to the ADA innovator Humira® in patients with moderate and severe psoriasis.Objective. The BCD-057-2/CALYPSO phase III...
প্রধান লেখক: | , , , , , , , , , , , , , , , , |
---|---|
বিন্যাস: | প্রবন্ধ |
ভাষা: | Russian |
প্রকাশিত: |
IMA-PRESS LLC
2018-12-01
|
মালা: | Современная ревматология |
বিষয়গুলি: | |
অনলাইন ব্যবহার করুন: | https://mrj.ima-press.net/mrj/article/view/865 |